Geron corp (GERN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-68,548

-27,017

-27,916

-29,537

-

-

-

-

-

-

-

Net loss

-

-

-

-

46

-35,670

-38,379

-68,881

-96,853

-111,377

-70,184

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

64

59

76

81

56

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

47

320

830

1,580

1,609

1,753

Accretion of discount on long-term debt

-

-

-

-

-

-

-

-

51

-

0

Loss on debt extinguishment

-

-

-

-

-

-

-

-

-1,664

-

0

Loss on retirement/sales of property and equipment

-

-

-5

16

-

-3

831

142

-5

-75

-130

Accretion and amortization on investments, net

1,534

978

-273

-552

-2,098

-2,889

-1,322

-2,184

-4,422

-3,568

-926

Change in fair value of equity investment, including foreign currency translation

196

604

-

-

-

-

-

-

-

-

-

Loss on write-downs of property and equipment

-

-

-

-

-

-

200

271

874

-

0

Loss on sales of marketable securities

-

-

-

-

-1

-

-

-

-2

-

0

Issuance of common stock in connection with acquired in-process research technology

-

-

-

-

-

-

-

-

594

27,500

0

Stock-based compensation for services by non-employees

68

191

200

156

364

253

252

183

744

-

-

Issuance of common stock in exchange for services by non-employees

-

-

-

-

-

-

-

-

-

8,673

4,866

Stock-based compensation for employees and directors

6,079

6,368

8,144

8,245

8,397

7,658

4,435

5,311

15,249

13,718

10,575

Amortization related to 401(k) contributions

9

9

32

61

161

111

-

-

-

-

-

Amortization of right-of use-assets

712

-

-

-

-

-

-

-

-

-

-

Amortization related to 401(k) contributions

-

-

-

-

-

-

458

726

709

647

494

Loss on equity method investment

-

-

-

-

-

-

-

-

-503

-2,347

-

Unrealized gain on derivatives

-

-

-

-

16

351

-316

13

643

190

-

Changes in assets and liabilities:
Loss on investments in licensees

-

-

-

-

-

-

-

-

-

-

1,364

Unrealized gain on fair value of derivatives

-

-

-

-

-

-

-

-

-

-

157

Interest and other receivables

-366

528

-39

-731

243

399

-188

-646

-401

479

436

Prepaid assets

-121

752

56

-123

-89

72

-1,081

-1,311

-4,085

-2,866

-3,019

Deposit and other assets

964

-

-

-

-

-

-

-

-

-

-

Deposits and other assets

-

-

-

-

-

-5

4

-112

658

45

99

Accounts payable

199

479

278

65

-873

-364

-2,032

449

-482

1,288

-56

Accrued compensation and benefits

2,188

-743

542

-183

-1,187

486

-431

3,548

944

5,401

4,166

Amount due to Janssen Biotech, Inc.

11,659

908

-1,665

1,039

-

-

-

-

-

-

-

Accrued collaboration charges

-

-

-

-

2,328

-

-

-

-

-

-

Accrued restructuring charges

-

-

-

-

-

-

-1,878

-1,758

3,730

-

-

Accrued restructuring charges

-

-

-

-

-

-

-

-

-

-

0

Accrued liabilities

6,211

391

-508

314

-417

-246

-1,697

-92

1,038

803

-265

Operating lease liabilities

-655

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-35,000

35,000

-

-

-350

-700

971

Advance payment from related party for research and development

-

-

-

-

-

-

-

-

-

-

-440

Translation adjustment

-

-

-

-

-

-

-

169

-1

4

1

Net cash used in operating activities

-

-

-

-

-

9,350

-36,680

-55,146

-62,392

-44,292

-

Net cash used in operating activities

-43,829

-21,009

-20,556

-18,369

-24,196

-

-

-

-

-

-43,374

Cash flows from investing activities:
Restricted cash transfer

-

-

-

-

1

-529

1

1

1

1

-25

Loan to related party

-

-

-

-

-

-

-

-

-

1,500

0

Investment in licensee, net

-

-

-

-

-

-

-

-

-

23

2,009

Purchases of property and equipment

413

16

-

57

90

131

3

862

612

836

1,435

Proceeds from sales of property and equipment

-

-

-

16

-

-

1,196

170

-

2

0

Purchases of marketable securities

153,467

188,365

100,006

129,250

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

206,459

190,263

88,977

79,369

144,890

183,414

200,109

Proceeds from sales/calls of marketable securities

-

-

-

-

4,242

10,549

-

-

809

-

0

Proceeds from maturities of marketable securities

181,280

110,663

122,976

138,054

202,381

101,412

108,839

141,016

176,832

137,320

120,524

Proceeds from sale of investment in licensees

-

-

-

-

-

-

-

-

1

-

1

Net cash provided by investing activities

-

-

-

-

-

-77,904

21,054

60,954

32,139

-48,452

-

Proceeds from issuance of long-term debt

-

-

-

-

-

-

-

-

6,422

-

0

Repayment of long-term debt

-

-

-

-

-

-

-

-

6,422

-

0

Distribution to TA Therapeutics, Ltd. shareholder

-

-

-

-

-

-

-

-

-

6

0

Net cash provided by (used in) investing activities

27,400

-77,718

22,970

8,763

73

-

-

-

-

-

-83,003

Cash flows from financing activities:
Proceeds from issuances of common stock under equity plans

204

6,951

51

1,169

-

-

-

-

-

-

-

Proceeds from issuances of common stock from financings

19,295

86,017

1,060

-

2,575

98,360

6,553

150

386

104,121

51,630

Net cash provided by financing activities

-

-

-

-

-

98,360

6,553

150

386

104,115

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

29,806

-9,073

5,958

-29,867

11,371

-

Net cash provided by financing activities

19,499

92,968

1,111

1,169

2,575

-

-

-

-

-

51,630

Net increase (decrease) in cash, cash equivalents and restricted cash

3,070

-5,759

3,525

-8,437

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-21,548

-

-

-

-

-

-74,747

Cash paid for interest

-

-

-

-

-

-

-

-

37

-

0